Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | MVD | P53602 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439118 | 1.00 | ACE (0.50) | ACERENMVD | |
| SCHEMBL29544133 | 1.00 | ACE (0.50) | ACERENMVD | |
| SCHEMBL15756757 | 0.97 | ACE (0.53) | ACERENMVD | |
| SCHEMBL13246638 | 0.97 | ACE (0.53) | ACERENMVD | |
| SCHEMBL1402277 | 0.86 | CHRM2 (0.42) | ACE | |
| SCHEMBL1402279 | 0.86 | CHRM2 (0.42) | ACE | |
| SCHEMBL6519298 | 0.85 | DPP4 (0.47) | ACE | |
| SCHEMBL26944075 | 0.85 | DPP4 (0.47) | ACE | |
| SCHEMBL29874508 | 0.84 | ACE (0.49) | ACERENMVD | |
| SCHEMBL29380104 | 0.84 | ACE (0.49) | ACERENMVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630598-B2 | IL-10 muteins and fusion proteins thereof | AMGEN INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260132222-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12479930-B2 | Proteins specific for BAFF and B7RP1 and uses thereof | AMGEN INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3689371-B1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC (US) | 2025-10-22 | — | — | EP | disclosed |
| CN-119213137-A | Treatment of adeno-associated virus with signal peptide modification using codon optimized nucleic acid encoding alpha-Glucosidase (GAA) for treatment of pompe disease | 阿斯克肋匹奥生物制药公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-110437336-B | Proteins specific for BAFF and B7RP1 and uses thereof | 美国安进公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20230265145-A1 | IL-10 MUTEINS AND FUSION PROTEINS THEREOF | AMGEN INC. | 2023-08-24 | — | — | US | disclosed |
| EP-4172184-A2 | IL-10 MUTEINS AND FUSION PROTEINS THEREOF | Amgen Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230128444-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-11492417-B2 | Proteins specific for BAFF and B7RP1 and uses thereof | AMGEN INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3456344-B1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC (US) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132222-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | SSB, IGSF11, CD22 | ACE 4384/4885REN 2144/4885MVD 2326/4885 |
| US-12630598-B2 | IL-10 muteins and fusion proteins thereof | MYH10, IL36G, S100A10 | ACE 4705/4885REN 4135/4885MVD 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.